Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180775 | 1.00 | TNF (0.46) | TNFCDK1CDK2PNMTBCHE | |
| Bromide SCHEMBL16701359 | 0.98 | TNF (0.45) | TNFCDK1CDK2PNMTBCHE | |
| SCHEMBL5550507 | 0.98 | TNF (0.45) | TNFCDK1CDK2PNMTBCHE | |
| Hydrochloric Acid SCHEMBL1307572 | 0.98 | TNF (0.45) | TNFCDK1CDK2PNMTBCHE | |
| Hydrochloric Acid SCHEMBL19358949 | 0.98 | TNF (0.45) | TNFCDK1CDK2PNMTBCHE | |
| SCHEMBL16738368 | 0.98 | TNF (0.45) | TNFCDK1CDK2PNMTBCHE | |
| SCHEMBL28326382 | 0.89 | TNF (0.38) | TNFCDK1CDK2PNMTBCHE | |
| SCHEMBL30239986 | 0.87 | CDK1 (0.39) | TNFCDK1CDK2PNMTBCHE | |
| SCHEMBL30239992 | 0.87 | CDK1 (0.39) | TNFCDK1CDK2PNMTBCHE | |
| SCHEMBL27963572 | 0.87 | CDK1 (0.39) | TNFCDK1CDK2PNMTBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732850-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | Antelope Therapeutics SAS (FR) | 2026-04-29 | — | — | EP | claimed |
| EP-3185329-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2026-04-22 | — | — | EP | claimed |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | claimed |
| US-20250345441-A1 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-11-13 | — | — | US | claimed |
| US-20250276067-A1 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-09-04 | — | — | US | claimed |
| EP-4588485-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND TOPOISOMERASE INHIBITOR AND USE THEREOF | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-07-23 | — | — | EP | claimed |
| WO-2025151746-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF POU2F3-DRIVEN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | claimed |
| CN-119855608-A | Pharmaceutical combination of FAK inhibitor and topoisomerase inhibitor and application thereof | 应世生物科技(南京)有限公司 | 2025-04-18 | — | — | CN | claimed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| CN-115710227-B | Preparation method of indenoisoquinoline derivative | 深圳万知达企业管理有限公司 | 2025-03-18 | — | — | CN | claimed |
| US-20130317018-A1 | Methods and Compositions for Unsilencing Imprinted Genes | UNITED STATES GOVERNMENT | 2013-11-28 | — | — | US | claimed |
| WO-2013160773-A2 | POLYMERIC NANOPARTICLES AND A PROCESS OF PREPARATION THEREOF | NANOGEN PHARMACEUTICALS (IN) | 2013-10-31 | — | — | WO | claimed |
| WO-2012064806-A2 | METHODS AND COMPOSITIONS FOR UNSILENCING IMPRINTED GENES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-05-18 | — | — | WO | claimed |
| CN-102316869-A | The treatment method for cancer | AMC AMSTERDAM | 2012-01-11 | — | — | CN | claimed |
| WO-2011130677-A1 | INHIBITORS OF CANCER STEM CELLS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-10-20 | — | — | WO | claimed |
| US-20100317628-A1 | MicroRNA Modulators and Method for Identifying and Using the Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | claimed |
| US-20090156629-A1 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | claimed |
| EP-2035016-A2 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES | Enzon Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2007146835-A2 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| EP-0643699-B1 | 6-(2-HYDROXYETHYLAMINOALKYL)-5,11-DIOXO-5,6-DIHYDRO-11H- INDENO[1,2-C]ISOQUINOLINES AND THEIR USE AS ANTINEOPLASTIC AGENTS | VUFB AS (CZ) | 1996-10-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317628-A1 | MicroRNA Modulators and Method for Identifying and Using the Same | AGO2, RNASE1, TRDMT1 | TNF 3157/4885CDK1 3730/4885CDK2 1150/4885 |
| US-20250345441-A1 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | MTHFD1, DHFR, ABCG2 | TNF 613/4885CDK1 1688/4885CDK2 1796/4885 |
| US-20250276067-A1 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | MTHFD1, DHFR, ABCG2 | TNF 613/4885CDK1 1688/4885CDK2 1796/4885 |
| US-20090156629-A1 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES | RECQL, BLM, SYNCRIP | TNF 3642/4885CDK1 1935/4885CDK2 3118/4885 |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | SYNJ1, MYT1, SYNJ2 | TNF 3700/4885CDK1 4327/4885CDK2 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.